Datopotamab deruxtecan Daiichi Sankyo (datopotamab deruxtecan)
- Region
- 🇪🇺 EU
- Active substance
- datopotamab deruxtecan
- Company
- Daiichi Sankyo Europe GmbH
- Status
- Application withdrawn
- Therapeutic area
- Carcinoma, Non-Small-Cell Lung
- Application
- EMEA/H/C/006081
- ATC
- L01FX35
- Official record
- www.ema.europa.eu
Indication
Treatment of adult patients with locally advanced or metastatic non squamous non-small cell lung cancer (NSCLC)
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Datroway Authorised · Daiichi Sankyo Europe GmbH
Follow Datopotamab deruxtecan Daiichi Sankyo
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.